About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT03558165

Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay

Currently, publicly funded standard of care testing in Ontario for stage IV lung cancer patients uses individual gene tests to look for mutations in the EGFR and ALK genes. This testing broadens treat...

Lead sponsor: University Health Network, Toronto•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University Health Network, Toronto

Collaborators

Princess Margaret Hospital, Canada
The Princess Margaret Cancer Foundation

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Age ≥ 18 years of age
•Pathologic or cytologic confirmation of lung adenocarcinoma (mixed adenocarcinoma and sarcomatoid features permitted)
•Stage IV disease
•Sufficient FFPE tumour tissue for OCCP testing
•Performance status 0-2
•Candidates for targeted therapy (TKIs) and/or clinical trials as determined by the patient's medical oncologist
•Prognosis \> 6 months
•Known translocations of RET, MET exon14 skipping variants, or MET amplification are allowed

Exclusion Criteria

•● Patients with known EGFR, KRAS, BRAF and ERBB2 mutations or ALK or ROS1 fusions at study entry unless acquired resistance to molecularly targeted therapy

Related studies

RECRUITINGPhase 2

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

NCT07250477 · Non-small Cell Lung Cancer Stage IIIC, Non-small Cell Lung Cancer Stage IV, and more

RECRUITINGEARLY Phase 1

[177Lu]Lu-AKIR001 First-in-human Study

NCT06639191 · Thyroid Gland Anaplastic Carcinoma, Poorly Differentiated Thyroid Carcinoma, and more

Not Yet RecruitingPhase 2

Screening for Brain Metastases

NCT07492121 · Lung Cancer Stage IV, Melanoma Stage IV, and more

TERMINATEDPhase 1/2

Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers

NCT05860296 · Lung Cancer, Nonsmall Cell, Lung Cancer Stage IV, and more

Not Yet RecruitingNA

Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial

NCT06848426 · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 17, 2022Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment134

Start dateMar 2018

Last updatedMay 17, 2022

Condition

Lung Cancer Stage IV

Locations shown

Princess Margaret Cancer Centre

Toronto, Ontario

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 17, 2022Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions